MAP3K5 and amyotrophic lateral sclerosis: The extended lifespan of SOD1 mice treated with ASK1 inhibitors is of particular significance, as riluzole and edaravone, the FDA-approved ALS treatments, do not alter the lifespan of SOD1 transgenic mice [99, 100].